Stratos Wealth Partners LTD. Reduces Holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Stratos Wealth Partners LTD. lowered its position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 19.8% during the fourth quarter, HoldingsChannel reports. The firm owned 335,840 shares of the company’s stock after selling 82,800 shares during the period. Stratos Wealth Partners LTD.’s holdings in Zevra Therapeutics were worth $2,801,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. International Assets Investment Management LLC lifted its stake in shares of Zevra Therapeutics by 594.0% in the third quarter. International Assets Investment Management LLC now owns 6,940 shares of the company’s stock worth $48,000 after buying an additional 5,940 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in Zevra Therapeutics by 15.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock valued at $91,000 after acquiring an additional 2,452 shares during the last quarter. Hunter Associates Investment Management LLC purchased a new position in Zevra Therapeutics in the 3rd quarter worth approximately $92,000. XTX Topco Ltd acquired a new position in shares of Zevra Therapeutics during the 3rd quarter worth approximately $94,000. Finally, China Universal Asset Management Co. Ltd. purchased a new stake in shares of Zevra Therapeutics in the fourth quarter valued at approximately $94,000. Institutional investors and hedge funds own 35.03% of the company’s stock.

Zevra Therapeutics Stock Down 1.4 %

Shares of NASDAQ:ZVRA opened at $7.77 on Friday. The company has a market capitalization of $414.73 million, a price-to-earnings ratio of -3.94 and a beta of 2.00. Zevra Therapeutics, Inc. has a 12-month low of $4.20 and a 12-month high of $9.76. The business has a 50-day moving average price of $8.40 and a 200 day moving average price of $7.98. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.25). Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The company had revenue of $3.70 million during the quarter, compared to analysts’ expectations of $5.04 million. During the same period last year, the firm posted ($0.40) earnings per share. Sell-side analysts expect that Zevra Therapeutics, Inc. will post -1.95 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently commented on ZVRA shares. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of Zevra Therapeutics in a research report on Wednesday, November 20th. Canaccord Genuity Group dropped their price objective on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a report on Thursday, November 14th. Finally, Cantor Fitzgerald upgraded shares of Zevra Therapeutics to a “strong-buy” rating in a research report on Wednesday, January 29th. Six research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Zevra Therapeutics currently has an average rating of “Buy” and a consensus price target of $21.57.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.